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odiﬁer of cell adhesion protein (MOCA; previously
called presenilin [PS] binding protein) is a
DOCK180-related molecule, which interacts
with PS1 and PS2, is localized to brain areas involved in
Alzheimer’s disease (AD) pathology, and is lost from the
soluble fraction of sporadic Alzheimer’s disease (AD) brains.
Because PS1 has been associated with 
 
 
 
-secretase activity,
MOCA may be involved in the regulation of 
 
 
 
-amyloid
precursor protein (APP) processing. Here we show that
the expression of MOCA decreases both APP and amyloid
 
 
 
-peptide secretion and lowers the rate of cell-substratum
adhesion. In contrast, MOCA does not lower the secretion
M
 
of amyloid precursor-like protein (APLP) or several additional
type 1 membrane proteins. The phenotypic changes caused
by MOCA are due to an acceleration in the rate of intra-
cellular APP degradation. The effect of MOCA expression
on the secretion of APP and cellular adhesion is reversed
by proteasome inhibitors, suggesting that MOCA directs
nascent APP to proteasomes for destruction. It is concluded
that MOCA plays a major role in APP metabolism and
that the effect of MOCA on APP secretion and cell adhesion
is a downstream consequence of MOCA-directed APP
catabolism. This is a new mechanism by which the expression
of APP is regulated.
 
Introduction
 
Alzheimer’s disease (AD)* is the most prevalent cause of
dementia in the elderly. AD is in part characterized patholog-
ically by the presence of extracellular plaques consisting
of deposits of the amyloid 
 
 
 
-peptides (A
 
 
 
s) derived from
 
 
 
-amyloid precursor protein (APP). APP is cleaved by three
 
proteolytic activities, 
 
 
 
-, 
 
 
 
-, and 
 
 
 
-secretases (Mills and
Reiner, 1999; De Strooper and Annaert, 2000). 
 
 
 
-Secretase
cleaves APP within the A
 
 
 
 peptide sequence, whereas 
 
 
 
-secre-
 
tase cleaves APP at the NH
 
2
 
 terminus of the A
 
 
 
 peptide se-
 
quence. APP
 
s
 
 
 
 and APP
 
s
 
 
 
 are the NH
 
2
 
-terminal fragments
generated by 
 
 
 
- and 
 
 
 
-secretases, respectively, whereas the
remaining fragments are cleaved at the COOH terminus of
the A
 
 
 
 peptide sequence by 
 
 
 
-secretase. The presence of mu-
tant genes that encode presenilins (PSs) PS1 and PS2 have
been linked to early onset familial Alzheimer’s disease (FAD)
(Rogaev et al., 1995; Sherrington et al., 1995), and an in-
creased deposition of A
 
 
 
 in plaques has been associated with
these mutations (Sherrington et al., 1995; Scheuner et al.,
1996). There are several proteins that interact with the PSs
(Van Gassen et al., 2000). Among these is the modifier of cell
adhesion protein (MOCA) (Kashiwa et al., 2000; Chen et al.,
2001). Although MOCA has 40% sequence homology with
DOCK180 and contains SH
 
3
 
 and Crk binding domains, its
function was unknown. Because MOCA binds PS1 and be-
cause PS1 has been associated with 
 
 
 
-secretase activities in
APP processing (Wolfe and Haass, 2001), it was asked if
MOCA is involved in the regulation of APP metabolism.
 
Results
 
MOCA reduces APP and A
 
 
 
 secretion
 
To investigate the effect of MOCA on APP protein secretion,
a rat nerve cell line called B103 (Schubert et al., 1974) was
stably transfected with APP
 
695 
 
and again with a plasmid har-
boring the full-length MOCA cDNA. B103 cells normally ex-
press little or no APP (Schubert et al., 1989) and no MOCA.
The expression of MOCA was detected in transfected clones
of B103 (APP
 
695
 
/MOCA) at levels similar to or less than
MOCA expressed in the mouse hippocampus (Fig. 1, A and
D). Secreted proteins from the stably transfected cells contain-
ing either an empty vector or the MOCA gene were first stud-
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ied by Western blotting using antibody 6E10, which recog-
nizes APP and amino acid residues 1–17 of human A
 
 
 
 (Kim
et al., 1990). The release of secreted APP (APP
 
s
 
) was de-
creased dramatically in all independently isolated clones ex-
pressing MOCA relative to clones containing empty vector
(Fig. 1 A). To determine the specificity of the MOCA effect
on APP secretion and eliminate the possibility of clonal varia-
tion, several control experiments were performed. First, a
transcriptional change was ruled out because the abundance
of APP mRNA was not altered by both Northern blot and re-
verse transcription (RT)-PCR analysis (Fig. 1 B). Second,
transient transfection of MOCA into B103 (APP
 
695
 
) cells led
to the reduction of APP secretion in an uncloned population
(Fig. 1 D). Third, the secretion of APP was not affected by the
overexpression of DOCK180, a protein which has a 40% ho-
mology with MOCA (Fig. 2 D). Fourth, the secretion of en-
dogenous APP
 
751
 
 was reduced in HEK293T cells expressing
MOCA (Fig. 1 D). Lastly, since APP is a type I integral mem-
brane protein we asked if MOCA alters the expression or se-
cretion (shedding) of six other proteins. The effect of MOCA
expression on the secretion of another large extracellular pro-
tein, 
 
 
 
-laminin, was examined; no difference was observed be-
tween cells transfected with APP and APP plus MOCA (Fig.
1 A). Neural cell adhesion molecule (N-CAM) is involved in
both homotypic and heterotypic cell–cell adhesions and ex-
pressed as several membrane-bound and secreted isoforms
through an alternative splicing mechanism (Gower et al.,
1988). No effect on the levels of intracellular N-CAM expres-
sion and/or N-CAM secretion was observed in B103 cells ex-
pressing MOCA (Fig. 1 A). A single band with molecular
weight 
 
 
 
130 kd is detected intracellularly, whereas the se-
creted N-CAM was aggregated into higher molecular weight
complexes (
 
 
 
300 kd) as described by others (Tavella et al.,
1994). Notch-1 is involved in crucial cell fate decisions dur-
ing development and the processing of Notch is similar to
 
 
 
-secretase–mediated cleavage of APP (Greenwald, 1998; De
Figure 1. Decreased APP secretion in nerve cells expressing the MOCA protein. (A) The levels of APP secreted by two clones (clones 7 and 
8) stably transfected with APP and MOCA and detected with the 6E10 antibody were significantly lower than those from cells only expressing 
APP. The expression level of another secreted protein,  -laminin, was not affected by MOCA. Identical amounts of protein (80  g) were 
loaded in each of the six lanes, and Western blot assays were performed. The secretion of N-CAM and the intracellular levels of N-CAM were 
also not affected by MOCA. Actin levels were used as loading control. (B) The levels of APP mRNA in the corresponding cells were not 
significantly different as shown by Northern hybridization and the RT-PCR analysis. (C) MOCA had a small effect on Notch-1 expression. 
Actin was used as loading control. Notch-1 expression was quantitated and presented as percent expression in APP695. (D) The secretion of 
APP was significantly reduced relative to controls in B103 cells transiently transfected with MOCA and in HEK-293T cells, which secrete 
endogenous APP751. The middle panels show MOCA expression, and the bottom panel shows that the secretion of  -laminin was not affected 
by MOCA in HEK293T cells. The quantitation of the APPs, laminin, N-CAM, and Notch-1 expression was determined by scanning of the 
respective blots of several clones expressing MOCA (n   3) and presented as the percentage of B103 APP695 (100%). (E) Expression of 
N-cadherin, E-cadherin, and APLP2 in B103 and HEK-293 cells, and the secretion of APLP2 in B103 cells. Actin served as a loading control. 
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Strooper et al., 1999; Struhl and Greenwald 1999; Ye et al.,
1999). Fig. 1 C shows that the expression of (intracellular)
full-length (mol wt 
 
 
 
300 kd), and truncated transmembrane
forms (mol wt 
 
 
 
120 kd) of Notch are only slightly altered in
B103 cells expressing MOCA. Finally, previous studies have
shown that the processing or metabolism of amyloid precur-
sor-like protein (APLP) and cadherins are regulated by PSs
(Naruse et al., 1998; Marambaud et al., 2002). No difference
in E-cadherin and APLP2 expression was observed, nor was
there a decrease in APLP2 secretion. In contrast, the expres-
sion level of N-cadherin was significantly increased in MOCA-
expressing B103 and 293T cells (Fig. 1 E). The above data
show that MOCA expression leads to the reduced secretion of
APP but not other type-1 membrane proteins.
Because PS1 is associated with 
 
 
 
-secretase cleavage of APP
(Wolfe and Haass, 2001) and in situ hybridization shows
that MOCA and PS1 are expressed in overlapping areas of
the brain and are colocalized on cells expressing both pro-
teins (Kashiwa et al., 2000), it was asked if the effect of
MOCA on APP secretion is altered by PS1 expression or ac-
tivity. The endogenous expression of PS1 was detected in
B103 cells using an antibody specific to rat PS1. Fig. 2 A
shows the abundant processed NH
 
2
 
-terminal fragments of
PS1 (mol wt 
 
 
 
19–21 kd). A very weak band with a mol wt
 
 
 
90 kd was also observed, which may be a complexed form
of PS1 (unpublished data). To block PS1-related 
 
 
 
-secretase
activities, several inhibitors, which are specific for 
 
 
 
-secre-
tase, were used. All of these agents have been shown to de-
crease A
 
 
 
 production with concomitant increases in the lev-
els of the corresponding COOH-terminal fragments at the
concentrations we used. 
 
 
 
-Secretase inhibitor II is a transi-
tion-state analogue, which selectively inhibits the 
 
 
 
-secretase
cleavage of APP and Notch-1 (Wolfe et al., 1998, 1999; De
Strooper et al., 1999; Berezovska et al., 2000). Several di-
peptidyl aldehydes (
 
 
 
-secretase inhibitor III [Z-LL-CHO],
 
 
 
-secretase inhibitor IV [2-naphthoyl-VF-CHO], 
 
 
 
-secre-
tase inhibitor V [Z-LF-CHO], and calpain inhibitor III [Z-
VL-CHO, Calp III]) were also tested (Higaki et al., 1995;
Figueiredo-Pereira et al., 1999; Sinha and Lieberburg, 1999).
No effect of 
 
 
 
-secretase inhibitors II and V on APP secretion
Figure 2. PS1 and APP secretion. (A) The expression of the endogenous PS1 in B103 cells was determined by Western blot analysis. (B) Effects 
of  -secretase inhibitors II (g-II) (50  M), III (g-III) (50  M), IV (g-IV) (5  M), and V (g-V) (10  M) on APP secretion and intracellular expression 
of COOH-terminal stubs in B103(APP695) and B103(APP695/MOCA) cells are shown. Effects of Calp III (100  M), MG132 (10  M), and lactacystin 
(Lact) (20  M) were tested as well. Cells were treated in the presence of various inhibitors for 16 h. (C) The secretion of APP in APP and 
MOCA-containing cells stably transfected with either wild-type human PS1 (clones 5, 6, 11, 13) or mutant form (L392V) (clones 1, A1, A12, 
A13). (D) Summary of the effect of MOCA on APPs secretion. The secretion of APPs was reduced by MOCA with further reduction of APPs 
secretion in cells coexpressing MOCA and elevated PS1. The secretion level of sAPP in cells coexpressing both MOCA and mutant PS1 (L392V) 
was lower than that in cells only transfected with mutant PS1 (L392V). Human PS1 holoproteins (hPS1FL) and the NH2-terminal fragment 
(hPS1NTF) were detected using monoclonal antibody recognizing PS1 (Borchelt et al., 1996). The overexpression of DOCK180 protein in 
B103 cells is also indicated. 
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was found in B103 cells expressing MOCA. APP secretion
was partially restored by 
 
 
 
-secretase inhibitors III and IV
and by Calp III in B103 cells expressing MOCA and wild-
type cells. As controls, MG132 and lactacystin dramatically
affected APP secretion and intracellular expression (see the
following). All of the secretase inhibitors were functional be-
cause they all increased the accumulation of COOH-termi-
nal stubs (Fig. 2 B). There was much less accumulation of
these molecules in MOCA-expressing cells, probably be-
cause of the limited substrate (APP) availability. Similar re-
sults were also observed in HEK293 cells stably transfected
with MOCA (unpublished data). In addition, the effect of
the overexpression of human PS1 on APP secretion was
studied (Fig. 2 C). The full-length wild-type or a mutant PS1
gene was stably transfected into the B103 (APP
 
695
 
/MOCA)
cells, and APP
 
s 
 
assayed. Fig. 2 C shows that APP
 
s
 
 release was
further reduced relative to cells expressing MOCA alone in
four independently isolated clones, which coexpress MOCA
and wild-type (WT) PS1 or the mutant (FAD) PS1 (L392V).
The effect of MOCA on APP secretion is summarized in
Fig. 2 D, which also shows human PS1 overexpression (Fig.
2 D, bottom).
To determine the effect of MOCA expression on A
 
 
 
 pep-
tide production, we transfected the MOCA gene into a
B103 cell line, which contains the FAD Swedish form of
APP (APP
 
sw
 
) and secretes A
 
 
 
 peptides into the medium (Xu
et al., 1999). The levels of APP
 
sw
 
 secretion were significantly
decreased in cells expressing MOCA (Fig. 3 A). The intra-
cellular levels of APP
 
sw
 
 were also decreased by MOCA (Fig.
3 B). Therefore, the effects of MOCA on APP
 
sw
 
 secretion
were similar to those on wild-type APP (Fig. 1). A
 
 
 
 secre-
tion into the culture medium was then measured by immu-
noprecipitation and radioautography (Fig. 3 C) and inde-
pendently by the sandwich ELISA (Fig. 3 D). The level of
A
 
 
 
 in the medium derived from B103 (APP
 
sw
 
/MOCA) cells
was considerably decreased compared with B103 (APP
 
sw
 
)
cells (Fig. 3, C and D). We could not detect the intracellular
expression of A
 
 
 
 in any of the B103 (APP
 
695
 
) or B103
(APP
 
sw
 
) cell lines using the techniques employed to assay ex-
tracellular A
 
 
 
. The above data show that MOCA decreases
the secretion of both APP and A
 
 
 
.
 
Reduced APP secretion is due to APP degradation
 
The decreased secretion of APP caused by MOCA may be
due to a blockage of the secretion pathway, which will cause
an intracellular accumulation of APP, a decrease in its rate of
synthesis, or an increase in the rate of APP degradation. To
distinguish between these alternatives, we first examined the
intracellular levels of APP. Full-length APP was reduced in
B103 cells containing APP
 
695
 
/MOCA relative to APP
 
695
 
 cells
as defined by two antibodies, 6E10 and 22C11 (Fig. 4, A and
B). In addition, the level of expression of the COOH-termi-
nal fragment of APP was diminished in cells stably transfected
with MOCA as determined by immunoprecipitation with the
CT-15 antibody, which recognizes the last 15 COOH-termi-
nal amino acid residues of APP
 
695
 
 (Fig. 4 C). These data rule
out the possibility that MOCA expression is enhancing the
intracellular accumulation of APP and suggest that the de-
creased APP secretion caused by MOCA expression is not due
to a direct blockage of the secretion pathways.
Because there is no increased intracellular accumulation of
APP in cells expressing MOCA, we investigated the effect of
MOCA on the turnover of APP by pulse–chase experiments.
Antibodies 6E10 and CT-15 specifically immunoprecipitate
the intracellular APP holoprotein, whereas antibodies GID
and 22C11 performed less well (Fig. 5 A). 6E10 was used in
Figure 3. Effect of MOCA on A -
secretion. (A) The levels of secreted and 
intracellular APPsw were examined in 
several B103 clones stably transfected 
with both APPsw and MOCA by Western 
blot analysis. The optical density of 
APPsw secretion was quantitated by 
NIH image, normalized to the APPsw 
vector alone level, and the data are 
presented as the percentage change plus 
or minus the standard error or the mean 
(n   3). (B) Intracellular APP was assayed 
by Western blotting with antibody 6E10 
and quantitated as above. (C) The 
[
35S]methionine-labeled (16 h) secreted 
A  peptides were immunoprecipitated 
with 6E10 antibody, separated in SDS–
polyacrylamide gels, and visualized by 
exposure to X-films. The optical density 
of A  secretion was quantitated by NIH 
image, and the data are presented as the 
percentage of change plus or minus the 
standard error or the mean (n   3). 
(D) The secreted A 1–40 peptides were 
measured by using a sandwich ELISA kit 
(Biosource International). Data from four 
separate experiments were combined 
and are presented as mean   SEM pgm 
of A  per mg cellular protein (n   16/
condition).Amyloid precursor metabolism | Chen et al. 83
the following experiments. B103 cells expressing either
APP695/vector or APP695/MOCA were labeled for 10 min in
[
35S]methionine-containing media and chased for 15, 30,
45, and 60 min in “cold,” serum-free conditioned media. In
control B103 (APP695/vector) cells, the APP protein level de-
creased gradually (Fig. 5 B). In contrast, the intracellular
APP protein level in B103 (APP695/MOCA) cells rapidly de-
creased. The initial levels after the 10-min labeling period
were also lower than controls in cells expressing MOCA, a
result which would be predicted for nascent proteins can be
very rapidly degraded after synthesis (Schubert et al., 2000).
There was a temporal increase in the amount of APP protein
in the medium of both cell types (Fig. 5 B), but the overall
level of APP accumulation in the medium is decreased by
the expression of MOCA (Figs. 1–3). Therefore, it is likely
that MOCA facilitates the degradation of APP. Finally, the
data in the following paragraphs rule out the remaining al-
ternative that MOCA expression down-regulates APP syn-
thesis, since in the presence of proteasome inhibitors the lev-
els of extracellular APP are similar in cells expressing MOCA
and controls.
Proteasomes mediate APP degradation
To independently verify the data on APP degradation, we
studied the effect of protease inhibitors on the secretion and
the intracellular accumulation of APP. Leupeptin inhibits ly-
sosomal proteases, whereas MG132 inhibits membrane pro-
tein degradation through the ubiquitin-proteasome pathway
(Soriano et al., 1999). Both APP secretion and the intracellu-
lar accumulation of APP were significantly increased in the
APP695/MOCA cells by 10  M MG132; no effect was ob-
served in cells treated with 100  M leupeptin (unpublished
data). More strikingly, the secretion of APP in cells express-
ing MOCA was enhanced in concert with the increasing du-
Figure 4. APP is not accumulated intracellularly in cells expressing 
MOCA. The intracellular levels of APP were detected in whole cell 
lysates by antibodies 6E10 (A) and 22C11 (B). (C) The cell lysates 
from the corresponding cells were immunoprecipitated with the 
antibody CT-15 and visualized by Western blot analysis. (D) Actin 
controls for protein loading.
Figure 5. MOCA alters the rate of intracellular APP protein 
degradation. (A) Antibody specificity was tested by immunoprecipi-
tation of [
35S]methionine-labeled protein using various antibodies 
including 6E10 (lane 1), 22C11 (lane 2), GID (lane 3), and CT-15 
(lane 4). Both the APP695 holoprotein in transfected B103 cells bearing 
the APP695 gene and the endogenous APP751 protein in HEK293 cells 
were immunoprecipitated by 6E10 and CT-15. (B) The turnover rate 
for intracellular APP holoprotein in APP695/vector and APP695/
MOCA (clone 8) cells was determined. The cells were labeled for 
10 min with [
35S]methionine and chased for the indicated time 
periods with cold medium. The cell lysates were collected and 
immunoprecipitated with antibody 6E10 (arrow is APP). The level 
of APP secretion was also determined at the same time. The optical 
density of APP expression was quantitated by NIH image, and the 
data are presented as the percentage change after normalization to 
the initial levels of APP (intracellular) or to the highest levels of APPs 
(n   3). (C) The effects of the protease inhibitor MG132 on the
secretion of APP. Cells were incubated in the presence and absence 
of MG132 (10  M) for the indicated time periods. The identical 
amount of protein collected from the serum-free condition medium 
was subjected to SDS-PAGE analysis, and the APP levels were 
determined by Western blot analysis. The secretion of APP was 
increased in APP695/MOCA (clone 8) cells treated by MG132 as a 
function of time. The optical density of APP secretion was quantitated 
from lower exposure images by NIH image, and the data are
presented as the percentage increase in APP, plus or minus the 
standard error of the mean (n   3).84 The Journal of Cell Biology | Volume 158, Number 1, 2002
ration of MG132 treatment and was nearly restored to con-
trol levels after 16 h (Fig. 5 C). These data again show that
the APP degradation is affected by MOCA. They also con-
firm the Northern and RT-PCR data, showing no effect of
MOCA on APP transcription, and rule out the possibility
that the expression of MOCA reduces APP synthesis.
To confirm the above data on protein degradation and
identify the mechanism which might be involved in the
MOCA regulation of APP degradation, the effects of addi-
tional protease inhibitors were tested. Cells were treated
with chloroquine (50  M), NH4Cl (5 mM), phosphorami-
don (2  M), N-acetyl-leucyl-norleucinal (ALLN) (27  M),
N-Ac-Leu-Leu-methioninal (ALLM) (27  M), lactacystin
(20  M), clasto-lactacystin  -lactone (20  M), or epoxomi-
cin (10  M) for 4 and 16 h, and the secretion and the intra-
cellular levels of APP were measured by Western blotting.
Lactacystin,  -lactone, and epoxomicin, which specifically
target the proteasome and do not inhibit lysosomal protein
degradation (Craiu et al., 1997; Fenteany and Schreiber,
1998; Meng et al., 1999), effectively restored the level of
APP secretion in MOCA-containing cells (Fig. 6 A). Similar
effects were also observed in cells treated with the peptide al-
dehydes, ALLN and ALLM, which inhibit proteasomes but
also inhibit lysosomal cysteine proteases and calpains (Sher-
wood et al., 1993; Zhang et al., 1999). In contrast, two lyso-
somal protease inhibitors, chloroquine and ammonium
chloride (Caporaso et al., 1992), did not reverse the MOCA
effects on APP secretion. As another negative control, phos-
phoramidon, a metalloprotease inhibitor, did not affect APP
secretion, consistent with the previous reports (Parvathy et
al., 1998). The effects of these inhibitors on the intracellular
levels of APP were also tested and were comparable to the
corresponding effects on APP secretion (Fig. 6 B). These
data were confirmed by a kinetic pulse–chase analysis. Cells
with and without MOCA were labeled for 10 min with
[
35S]methionine and chased in complete medium in the
presence of 10  M MG132. Fig. 7 A shows that nascent
APP molecules are stabilized by proteasome inhibition and
that the rate of loss of intracellular APP in cells expressing
MOCA becomes similar to that of MOCA-deficient cells.
These data strongly support the involvement of proteasomes
in the regulation of APP degradation by MOCA.
To determine if MOCA itself is affected by proteasome inhi-
bition, MOCA expression patterns were studied as a function
of time by Western blotting and confocal microscopy in the
presence of MG132. The accumulation of intracellular
MOCA increased after MG132 treatment (Fig. 7 B). Confocal
images showed that under normal conditions MOCA is widely
dispersed in the cytoplasm of B103 nerve cells (Fig. 7, C-2).
MG132 treatment caused an increase in MOCA accumulation
in the cytoplasm, and after 16 h treatment with MG132, there
was MOCA accumulation in the perinuclear areas (Fig. 7, C-5).
These data suggest that like many other proteins MOCA me-
tabolism is regulated by the proteasome pathway.
MOCA reduces cell-substratum adhesion
The profound decrease in APP secretion caused by MOCA
should have biological consequences. APP has multiple
functions, but its ability to mediate cell-substratum adhe-
sion has been well-documented (Schubert et al., 1989;
Chen and Yankner, 1991; Schubert and Behl, 1993; Jin et
al., 1994; Beher et al., 1996; Coulson et al., 1997). Be-
cause the inhibition of APP synthesis by antisense nucle-
otides blocks cell-substratum adhesion (Coulson et al.,
1997), it would be predicted that the expression of MOCA
has a similar effect and that this phenotype would be re-
versed by proteasome inhibitors, which restore APP accu-
mulation and secretion. This is indeed the case when the
ability of B103 nerve cells, expressing APP, MOCA, or
both, to adhere to the extracellular matrix protein laminin
Figure 6. Effects of different protease inhibitors on the secretion 
of APP. (A) Equal numbers of cells were incubated in the presence 
of various protease inhibitors including chloroquine (Chl) (50  M, 
lane 2), NH4Cl (5 mM, lane 3), phosphoramidon (PAD) (2  M, lane 
4), ALLN (27  M, lane 5), ALLM (27  M, lane 6), lactacystin (Lact) 
(20  M, lane 7), clasto-lactacystin  -lactone (Lactone) (20  M, lane 
8), epoxomicin (Epo) (10  M, lane 9), and MG132 (10  M, lane 10) 
for 4 and 16 h. The secretion of APP was increased in APP695/
MOCA (clone 8) cells treated by ALLN, ALLM, lactacystin, 
clasto-lactacystin  -lactone, or epoxomicin. In contrast, the effect 
of MOCA on APP secretion was not reversed in cells treated with 
chloroquine, NH4Cl, or phosphoramidon. (B) Effects of different 
protease inhibitors on the intracellular levels of APP were assayed 
as well, and the experiments were performed as described in A 
except that the cell lysates were used. Actin was used as loading 
control (unpublished data).Amyloid precursor metabolism | Chen et al. 85
are compared. Fig. 8 A shows that the expression of APP695
in B103 cells, which normally lack APP, increases the rate
of cell-substratum adhesion to laminin. The expression of
MOCA alone in B103 cells lacking APP695 has no effect on
adhesion. In contrast, cells expressing both APP and
MOCA adhere to laminin at a rate which is indistinguish-
able from cells expressing no APP. However, when cells ex-
pressing APP and MOCA are exposed to the proteasome
inhibitor lactacystin for 5 h before the adhesion assay there
is an increase in the rate of adhesion to a level indistin-
guishable from cells expressing APP but no MOCA (Fig. 8
B). Lactacystin does not alter the rate of adhesion of cells
which do not express MOCA or wild-type B103 cells. The
adhesion data are in agreement with those which show that
MOCA expression increases APP breakdown and decreases
its secretion (Figs. 1, 2, and 5) and that APP accumulation
and secretion can be restored by proteasome inhibitors
(Figs. 5 and 6).
Discussion
The above data show that MOCA decreases the secretion of
APP and A  and also reduces the rate of cell adhesion.
These results reflect the acceleration of intracellular APP
Figure 7. Proteasome inhibitors block the degradation of nascent APP. (A) Pulse–chase analysis of intracellular APP in cells expressing 
MOCA or no MOCA in the presence of MG132 (10  M). Cells were labeled for 10 min with [
35S]methionine and then chased with normal 
medium. The rate of intracellular decline was determined relative to the initial level of APP in each cell type. The data are the mean of triplicate 
determinations plus or minus the standard error of the mean. (B) Western blotting of MOCA in the presence of MG132 (10  M) at indicated 
times. (C) Confocal images of cells show an increase in MOCA accumulation in B103 (APP695/MOCA) cells. The expression of MOCA was 
analyzed with a MOCA antibody and visualized by staining with Texas red–conjugated secondary antibodies. Control, secondary Texas Red–
conjugated antibody stain only (C-1); no MG132 (C-2); MG132-treated cells (4 h) (C-3) ; MG132-treated cells (8 h) (C-4); MG132-treated 
cells (16 h) (C5).
Figure 8. The expression of MOCA 
decreases cell-substratum adhesion. 
Exponentially growing cells were labeled 
with 
3H-leucine overnight, and their rate 
of adhesion to laminin was determined as 
a function of time as described in Materials 
and methods. (A) O, B103; x, B103 
APP695;  , B103 MOCA Cl 3;  , B103 
APP695/MOCA Cl 8. (B) O, B103/APP695Cl 
1 with empty vector; x-B103/APP695 with 
empty vector plus LC;  -B103/APP695/
MOCA Cl 8 plus LC;  -B103/APP695/
MOCA. In some cells, 25  M lactacystin 
(LC) was added to the cultures 5 h before 
the adhesion assay. The data are presented 
as the mean plus or minus the standard 
error of the mean for triplicate determi-
nations. The experiment was repeated 
three times with similar results.86 The Journal of Cell Biology | Volume 158, Number 1, 2002
degradation for the following reasons. (a) There is no accu-
mulation of intracellular APP nor is there a decrease in APP
mRNA in cells expressing MOCA. (b) In pulse–chase exper-
iments, the intracellular APP protein level is rapidly reduced
in cells expressing physiological levels of MOCA relative to
cells not expressing MOCA. (c) The level of APP secretion
and the remaining COOH-terminal fragments of APP are
decreased by MOCA to a similar extent. (d) Several protea-
some inhibitors increase the accumulation of intracellular
APP and reverse the effect of MOCA on APP secretion and
cell adhesion; lysosomal protease inhibitors are ineffective.
(e) Pulse-labeled APP is also stabilized by proteasome inhib-
itors in MOCA-expressing cells, and unlike in the absence of
proteasome inhibitors, its rate of intracellular decline is in-
distinguishable from that in cells not expressing MOCA.
APP is a type I membrane-spanning protein whose secre-
tion is regulated by a variety of factors including growth fac-
tors, neurotransmitters, phorbol esters, extracellular matrix
molecules, and stress (Schubert et al., 1989; Mills and Reiner,
1999; De Strooper and Annaert, 2000). The mechanisms in-
volved in the regulation of APP secretion include alternations
in APP phosphorylation (Caporaso et al., 1992), the modifi-
cation of protein glycosylation (Galbete et al., 2000), alterna-
tive in gene splicing (Shepherd et al., 2000) and transcription
(Ciallella et al., 1994), and also changes in protein degrada-
tion (Checler et al., 2000). Although these mechanisms are
diverse, it is likely that they are shared with many type I
membrane proteins. APP is probably the most studied mole-
cule of this class because of its medical importance.
The intracellular sites of APP metabolism still remain con-
troversial with  -secretase cleavage described at the plasma
membrane, in the Golgi, or in the post-Golgi secretory vesi-
cles (Mills and Reiner, 1999). Similarly,  - and  -secretase
activities have been identified in the trans-Golgi network
(Xu et al., 1997), the endoplasmic reticulum/intermediate
compartment (Cook et al., 1997), and the endosome/lyso-
some system (Haass et al., 1992). Our data do not distin-
guish between these alternatives but show that secretion of
APP and A  are both reduced in the presence of MOCA.
Because we do not observe an intracellular accumulation of
APP or intermediate breakdown products of APP, the effect
of MOCA on APP processing most likely occurs before APP
reaches the cell surface. The pleotropic effects of MOCA on
APP degradation may occur in the ER, which is consistent
with the subcellular localization of both PS1 and MOCA
(Doan et al., 1996; Kashiwa et al., 2000; Xia et al., 2000.
Proteins destined for membranes or secretion are translo-
cated into the ER, folded, assembled, and transported to a
cellular destination or secreted (Hurtley and Helenius, 1989).
Incorrectly folded proteins, unassembled subunits of multi-
subunit complexes, and mutated proteins are rapidly elimi-
nated from the cell; misfolded proteins are translocated to
proteasomes and degraded (Suzuki et al., 1998). However, in
the case of unfolded proteins the conventional route may not
be taken because excessive accumulation of these macromole-
cules within the ER lumen might lead to their aggregation
and precipitation, thereby blocking the secretory pathway
(Klausner and Sitia, 1990). Because APP binds to the molec-
ular chaperones Bip/G-RP78 and HSC73 and misfolded
proteins bound to Bip/GRP78 are degraded, it has been sug-
gested that APP can be retained in the ER as a nascent
polypeptide and degraded (Yang et al., 1998; Kouchi et al.,
1999). This idea is consistent with data suggesting that the
degradation pathway for APP in the ER participates in APP
secretion and is distinct from  -secretase cleavage (Bunnell et
al., 1998) and that the proteasome is involved in APP pro-
cessing (Hare, 2001). Because APP secretion is restored by
proteasome inhibitors and intracellular accumulation of APP
is not observed in the absence of proteasome inhibitors, the
secretion pathway is not blocked by MOCA. Consistent with
previous data (Bunnell et al., 1998), we were unable to isolate
a ubiquitin-conjugated APP complex even after the treatment
with proteasome inhibitors, and we did not observe any APP
intermediates caused by MOCA expression.
Proteasome inhibitors increase the stability of both total
and pulse-labeled APP in cells (Figs. 6 and 7) and restore the
secretion rate to near control levels in MOCA-expressing
cells (Fig. 5 C and Fig. 6). They also increase the intracellu-
lar accumulation of MOCA over long periods of time (Fig.
7). Although it cannot be formally ruled out in any studies
that proteasome inhibitors block an unknown function to
generate the resultant phenotype, we feel that this is unlikely
in the experiments described here for two reasons. First, in
an experiment where cells are pulse labeled for 10 min and
chased in the presence of a proteasome inhibitor there was a
rapid inhibition of APP breakdown, bringing it up to the
rate of loss of intracellular APP in non-MOCA cells due to
secretion (Fig. 7). The effect occurred well before any signif-
icant accumulation of other proteins like MOCA. The accu-
mulation in proteins in the ER in the presence of protea-
some inhibitors can sometimes indirectly inhibit the secretory
pathway; in our case, APP secretion is enhanced. Second, a
variety of structurally diverse proteasome inhibitors reversed
the effect of MOCA on APP secretion, whereas  -secretase
inhibitors, lysosomal protease inhibitors, and a metallopro-
tease inhibitor have no effect. These results strongly suggest
that proteasomes are involved in MOCA-induced APP deg-
radation. These data also suggest that nascent APP may pass
through an ER environment in which complexes for both
protein degradation and protein assembly coexist. In the ab-
sence of MOCA, the precursor protein follows the secretory
pathway, whereas the expression of MOCA directs a signifi-
cant fraction of APP to proteasomes where it is degraded.
This novel MOCA-mediated pathway presents yet another
way in which the expression of specific proteins may be con-
trolled.
A  amyloid peptides are also generated from various cellu-
lar compartments, including the ER, the Golgi apparatus, the
trans-Golgi networks, lysosomes, and endosomes, through ei-
ther a constitutive secretion pathway or through an endocy-
totic pathway in which cell surface APP moves to the lyso-
somes or endosomes where A  is produced (Mills and Reiner,
1999; De Strooper and Annaert, 2000). A  secretion is de-
creased by MOCA in our studies, probably because of the
rapid degradation of APP, therefore reducing the APP source
for the generation of A . Because the overall production of
A  is reduced by MOCA, MOCA expression may help to re-
duce A  production in the central nervous system. It follows
that the loss of MOCA function could lead to AD.
PS1 controls several aspects of APP metabolism (Sisodia,Amyloid precursor metabolism | Chen et al. 87
2000) and protein breakdown (Niwa et al., 1999; Katayama
et al., 2000). PS1 is also required for “ -secretase” cleavage of
Notch-1. However, the proteolytic cleavage of APP and
Notch are differentially facilitated (Capell et al., 2000). The
PS1-dependent  -secretase processing of APP appears to be
nonselective and occurs at multiple sites within the APP trans-
membrane domain. This is in contrast to the highly selective
PS1-dependent processing of Notch (Yu et al., 2001). Our
data show that, unlike PS1, MOCA has a minimal effect on
Notch-1 degradation and that of five additional membrane
proteins (Fig. 1). We also studied the effects of several selec-
tive   -secretase inhibitors on APP secretion modulated by
MOCA (Fig. 2 B). Consistent with previous observations,
there was little effect of these  -secretase inhibitors on APP se-
cretion in the absence of MOCA. In contrast to the protea-
some inhibitors, among the  -secretase inhibitors tested, only
 -secretase inhibitors III and IV and Calp III partially revert
the effect of MOCA effect on APP secretion.  -Secretase in-
hibitor II, which has no effect, is thought to be an aspartyl
protease inhibitor, which selectively inhibits the  -secretase
cleavage of APP and Notch-1 proteolysis (Wolfe et al., 1998;
1999; De Strooper et al., 1999; Berezovska et al., 2000; Esler
et al., 2000). The other  -secretase inhibitors including III,
IV, V, and the potent calpain inhibitor III are dipeptidyl alde-
hydes targeting cysteine proteases and may block proteasome
enzymes, accounting for the inconsistency of their effects on
APP secretion affected by MOCA. Finally, the additive effect
of PS1 on MOCA-decreased APP secretion was demonstrated
(Fig. 2 C). This observation is consistent with the fact that
PS1 lowers the secretion of APP in yeast (Evin et al., 2000).
MOCA also functions effectively in the presence of mutant
PS1. Together, the above data show that the effect of MOCA
is very different from that of the PS1-associated  -secretase ac-
tivity. MOCA contains an SH3 domain, interacts with the
Crk adaptor protein, and shares a 40% homology with
DOCK180 (Kashiwa et al., 2000). Because DOCK180 inter-
acts with Rac and other small G-proteins, MOCA may also
interact with small G-proteins involved in protein breakdown
or mediate phosphorylation events between proteins involved
in APP trafficking and metabolism.
APP is a potent cell adhesion molecule which binds to
both heparin and other extracellular matrix molecules
(Schubert et al., 1989; Beher et al., 1996; Wu et al., 1997).
Cells which express APP adhere more rapidly to extracellular
matrix proteins than cells which do not (Fig. 8) (Schubert
and Behl, 1993). Conversely, the inhibition of APP synthe-
sis by antisense techniques blocks cell-substratum adhesion
(Coulson et al., 1997). The expression of MOCA in B103
nerve cells, which do not make APP, has no effect on cellular
adhesion to laminin, but reduces the rate of adhesion of cells
which express APP (Fig. 8). Therefore, the effect of MOCA
on cell-substratum is tightly coupled to APP expression.
When the rapid breakdown of APP caused by MOCA is
blocked by proteasome inhibitors, there is a return to the
normal rate of adhesion for B103 cells expressing APP (Fig.
8 B). The simplest explanation for these results is that in the
presence of MOCA newly synthesized APP is degraded at
such a rapid rate that very little reaches the cell surface so
that it is unable to participate in adhesive interactions. Be-
cause one adhesion-dependent biological activity of APP is
the regulation of neurite outgrowth (Jin et al., 1994), the ex-
pression of MOCA during development could regulate cell
migration and axon pathfinding. Therefore, the aberrant ex-
pression of MOCA or its loss could have pathological conse-
quences in addition to those caused by altered A  secretion.
Materials and methods
Antibodies and chemicals
Monoclonal antibody 22C11, which recognizes amino acid residues 66–
81 of APP695, was purchased from Roche. Anti-GID, a rabbit polyclonal
antibody against amino acid residues 175–186 of APP695, was provided by
Dr. Greg Cole (University of California, Los Angeles, CA) and has been
well characterized (Schubert et al., 1989). CT-15, a rabbit polyclonal anti-
body against the last 15 COOH-terminal amino acid residues of APP695,
was provided by Dr. Edward Koo (University of California, San Diego, CA).
Monoclonal antibody 6E10, which recognizes amino acid residues 1–17
of human A , was obtained from Dr. Richard Kiscsak (New York State In-
stitute for Basic Research, Staten Island, NY) or purchased from Senetek.
An affinity purified polyclonal antibody, which recognizes amino acid res-
idues 2,012–2,027 of MOCA, was generated in rabbits (Kashiwa et al.,
2000). A monoclonal antibody, recognizing the NH2-terminal amino acid
residues 21–80 of human PS1, and a polyclonal antibody, recognizing the
amino acid residues 303–316 of mouse PS1, were purchased from Chemi-
con and Oncogene, respectively.  -Laminin antibody (sc-6018), N-CAM
antibody (sc-1507), N- and E-cadherin antibody from Transduction Labo-
ratories, Notch antibody (sc-6014) were purchased from Santa Cruz Bio-
technology, Inc., and APLP was from Dr. Gopal Thinakaran (University of
Chicago, Chicago, IL). The following chemical reagents were bought from
Sigma-Aldrich: chloroquine, NH4Cl, phosphoramidon, ALLN, ALLM, lac-
tacystin, clasto-lactacystin  -lactone, leupeptin, and MG132. Epoxomicin
was bought from Biomol.  -Secretase inhibitors II, III, IV, and V and
calpain inhibitor III were purchased from Calbiochem.
Cells and transfection
The neuronal cell line B103 (Schubert et al., 1974) was grown in DME sup-
plemented with 10% heat-inactivated FBS. B103 cells were stably trans-
fected with APP695 using G418 selection (Schubert et al., 1989) and with var-
ious plasmids by Lipofectamine 2000 (Invitrogen) using puromycin selection
for MOCA or hygromycin for PS1. The stably transfected cells were subse-
quently cloned and screened for protein expression by Western blot analysis.
Western blotting, metabolic labeling, 
immunoprecipitation, and ELISA
For Western blotting, cells were washed twice with ice-cold PBS and
lysed in lysis buffer (1% Triton, 50 mM Hepes, pH 7.5, 50 mM NaCl, 5
mM EDTA, 1 mM Na3VO4, 50 mM NaF, 10 mM Na4P2O7, plus a mixture
of protease inhibitors [Complete Mini; Roche]). For secreted protein anal-
ysis, semiconfluent cultures (10
6 cells in 100-mm tissue culture dishes)
were washed twice with serum-free medium and incubated for 20 h in 4
ml serum-free medium. The growth conditioned medium was then de-
salted by passage through a Sephadex G25 column, and 10% of the mate-
rial was used to determine protein content. For a given experiment, equal
amounts of protein (usually 15  g) were lyophilized and resuspended in
50  l of sample buffer. Protein concentrations were determined by Coo-
massie Plus (Pierce Chemical Co.). The same amount of protein from
each sample was separated on Novex precast 10% polyacrylamide gels
(Invitrogen) and transferred to Immobulin membranes (Millipore). The
membranes were blocked with 5% nonfat milk in Tris-buffered saline for
1 h at room temperature. After overnight incubation at 4 C with primary
antibodies, the antigens were detected with HRP-conjugated secondary
antibodies (Bio-Rad Laboratories) using an ECL kit (Amersham Pharmacia)
and exposed to film. For pulse–chase experiments, cells were grown to
80% confluency and incubated in methionine-free DME for 90 min. Cells
were labeled with [
35S]methionine (400  Ci/ml in methionine-free DME
plus 5% dialyzed FBS) for 10 min at 37 C, and the medium was replaced
with serum-free DME medium plus N1 supplement (Sigma-Aldrich). The
media were collected, and cells were lysed after different time periods.
Protein concentrations were determined, and the same amounts of pro-
tein were immunoprecipitated with antibodies at 4 C overnight. 25  l of
anti–mouse IgG agarose (Roche) were then added to each sample and in-
cubated at 4 C for 2 h on a rocker platform. The immunoprecipitates were
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buffer (0.1% Triton, 20 mM Hepes, 150 mM NaCl, 10% glycerol). The
agarose beads were resuspended in 30  l SDS-PAGE sample buffer and
boiled for 3 min to release the proteins. After 2 min of centrifugation, the
supernatants were separated on 10% Tris-glycine gels. For A  analysis,
10–20% acrylamide Tricine gels and longer incubation times were used.
The gels were dried and subjected to autoradiography and quantitated by
NIH image. A  production was also measured by a sensitive fluores-
cence-based sandwich ELISA assay using a kit from Biosource Interna-
tional according to the manufacturer’s instructions.
Northern hybridization and RT-PCR
Total RNA was isolated from the cells and brain tissues using Trizol re-
agents (Invitrogen), and mRNA was purified using a mRNA purification kit
(Amersham Pharmacia Biotech). 2  g of mRNAs from each sample were
separated on 1% agarose gels and transferred onto Zeta membranes (Bio-
Rad Laboratories, Inc.). Northern hybridization was performed in a Ul-
traHyb buffer (Ambion) with an APP cDNA fragment probe labeled with
32P-dCTP using a rediprime kit (Amersham Pharmacia Biotech). RT reac-
tions were performed for each RNA sample using 1  g of total RNA in RT
buffer composed of 10 mM DTT, 20  M each of dATP, dCTP, dGTP, and
dTTP, and 1  M of oligo (dT). The solution was heated to 65 C for 5 min
and cooled to 37 C for 10 min, and then incubated in the presence of 25 U
of AMV RT at 42 C for 1 h. Master mixes for the PCR reactions were used
for each sample. The PCR reaction mixture contained forward and reverse
primers (10–20 pmol each), dNTPs (200  M each as final concentration),
1  PCR buffer, Taq DNA polymerase (0.5 U) (Roche), and 1  l of the RT
mixture as the source of cDNA. The primers used for PCR reaction were as
follows: 5 -ATGGATGCAGAATTCCGACATGAC-3  (forward) (nt 1,933–
1,956) and 5 -CTAGTTCTGCATCTGCTCAAAGAA-3  (reverse) (nt 2,235–
2,212) for the APP gene (sequence data available from GenBank/EMBL/
DDBJ under accession no. Y00264). Amplification was performed at 94 C
for 40 s, 56 C for 1 min, and 72 C for 1 min, for 35 cycles. The PCR reac-
tions with primers and RNAs but without the RT reaction were conducted
as controls. After amplification, each sample was electrophoresed on a
1.5% agarose gel visualized by ethidium bromide staining.
Adhesion assay
The cell adhesion assays were performed as described previously (Schu-
bert et al., 1989). Exponentially B103 (APP695/Vector) and B103 (APP695/
MOCA) cells were labeled with [
3H]leucine for 15 h. The cells were pipet-
ted from the culture dishes and washed three times by centrifugation with
Hepes buffered medium containing 0.4% BSA (Calbiochem). No trypsin or
chelating reagents were used. Aliquots of 0.2 ml containing 5   10
4 cells
were pipetted into 35-mm plastic Petri dishes coated with 5  g mouse
laminin and 2 ml of the above medium. The cells did not attach to un-
coated dishes. At the indicated times, the dishes were swirled 10 times, the
medium was aspirated, the remaining attached cells were dissolved in 3%
Triton X-100, and their isotope content was determined. The data are plot-
ted as the percent of input cells (radioactivity) that adhered at the indicated
time and are presented as the average of triplicate plates. Variation be-
tween duplicates was  5%.
Immunostaining and laser confocal imaging
Cultured cells were fixed in 4% paraformaldehyde for 20 min and perme-
abilized with 0.2% Triton X-100 for 30 min. The fixed cells were blocked
in 2% BSA in PBS for 1 h and incubated with primary antibodies followed
by fluorescent-conjugated secondary antibodies (Molecular Probes). The
cells were then mounted under glass coverslips with antifading media con-
taining 4% N-propyl gallate (Sigma-Aldrich). The cells were examined
with a Carl Zeiss MicroImaging, Inc. LSM 5 PASCAL laser scanning micro-
scope. 0.5- M-thick serial optical sections of the cells were recorded us-
ing the Carl Zeiss MicroImaging, Inc. LSM 5 Image Examiner software to
obtain images with pixel intensity within a linear range.
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